Thomas Ebenhan

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Topics

Positron Emission Tomography

Radiation Therapy

Top Venues

European journal of nuclear medicine and molecular imaging

Journal of labelled compounds & radiopharmaceuticals

Angewandte Chemie (International ed. in English)

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Janke Kleynhans, Thomas Ebenhan, Frederik Cleeren, Machaba Michael Sathekge
Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy? European journal of nuclear medicine and molecular imaging 51 (7) (2024)
Janke Kleynhans, Thomas Ebenhan, Frederik Cleeren, Machaba Michael Sathekge
Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy? European journal of nuclear medicine and molecular imaging 51 (7) (2024)
Janke Kleynhans, Thomas Ebenhan, Frederik Cleeren, Machaba Michael Sathekge
Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy? European journal of nuclear medicine and molecular imaging (2024)
Christiaan A Gouws, Tricia Naicker, Beatriz G de la Torre, Fernando Albericio, Janie Duvenhage, Hendrik G Kruger, Biljana Marjanovic-Painter, Sipho Mdanda, Jan R Zeevaart, Thomas Ebenhan, Thavendran Govender
68 Ga Radiolabeling of NODASA-Functionalized Phage Display-Derived Peptides for Prospective Assessment as Tuberculosis-Specific PET Radiotracers. Journal of labelled compounds & radiopharmaceuticals (2024)
Janke Kleynhans, Thomas Ebenhan, Frederik Cleeren, Machaba Michael Sathekge
Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy? European journal of nuclear medicine and molecular imaging 51 (7) (2024)
Liesbeth Everix, Elsie Neo Seane, Thomas Ebenhan, Ingeborg Goethals, Julie Bolcaen
Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy. Pharmaceuticals (Basel, Switzerland) 16 (2) (2023)
Arno Christiaan Gouws, Hendrik Gerhardus Kruger, Olivier Gheysens, Jan Rijn Zeevaart, Thavendran Govender, Tricia Naicker, Thomas Ebenhan
Antibiotic-Derived Radiotracers for Positron Emission Tomography: Nuclear or "Unclear" Infection Imaging? Angewandte Chemie (International ed. in English) 61 (45) (2022)
Janine Suthiram, Thomas Ebenhan, Biljana Marjanovic-Painter, Machaba Michael Sathekge, Jan Rijn Zeevaart
Towards Facile Radiolabeling and Preparation of Gallium-68-/Bismuth-213-DOTA-[Thi8, Met(O2)11]-Substance P for Future Clinical Application: First Experiences. Pharmaceutics 13 (9) (2021)
Janke Kleynhans, Machaba Michael Sathekge, Thomas Ebenhan
Obstacles and Recommendations for Clinical Translation of Nanoparticle System-Based Targeted Alpha-Particle Therapy. Materials (Basel, Switzerland) 14 (17) (2021)
Vusani Mandiwana, Lonji Kalombo, Rose Hayeshi, Jan Rijn Zeevaart, Thomas Ebenhan
Preclinical Assessment Addressing Intravenous Administration of a [68Ga]Ga-PSMA-617 Microemulsion: Acute In Vivo Toxicity, Tolerability, PET Imaging, and Biodistribution. Molecules (Basel, Switzerland) 26 (9) (2021)
Thomas Ebenhan, Janke Kleynhans, Jan Rijn Zeevaart, Jae Min Jeong, Mike Sathekge
Non-oncological applications of RGD-based single-photon emission tomography and positron emission tomography agents. European journal of nuclear medicine and molecular imaging 48 (5) (2020)
Janke Kleynhans, Sietske Rubow, Jannie le Roux, Biljana Marjanovic-Painter, Jan Rijn Zeevaart, Thomas Ebenhan
Production of [68 Ga]Ga-PSMA: Comparing a manual kit-based method with a module-based automated synthesis approach. Journal of labelled compounds & radiopharmaceuticals 63 (13) (2020)